| Vasculogenic erectile dysfunction: newer therapeutic strategies. | |
| | |
MedLine Citation:
|
PMID: 12853769 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
PURPOSE: Despite recent advances in therapy, reversal of vasculogenic erectile dysfunction (ED) is rarely possible. A review of vasculogenic ED may further our understanding of the underlying pathophysiology and help develop more effective curative therapy. MATERIALS AND METHODS: We reviewed the mechanisms of vasculogenic erectile dysfunction and discuss the therapies currently available or being developed for possible future use. RESULTS: Penile erection is a complex neurovascular phenomenon that may be affected by hypercholesterolemia, atherosclerotic vascular occlusive disease, veno-occlusive dysfunction and cavernosal fibrosis. Animal models of diffuse pelvic atherosclerosis can be maintained by feeding oral cholesterol and injuring the arterial endothelium. Impaired inflow may be addressed by penile revascularization but this strategy is applicable only in select cases. Neovascularization using vascular growth factors has recently been demonstrated to be feasible in animal models. Permanent reversal of impaired cavernosal relaxation requires control of hypercholesterolemia and lifestyle changes, such as smoking cessation. Cavernosal fibrosis may be reversible via some of the same approaches used in treating Peyronie's disease but to date little clinical success has been reported. Venous ligation appears to have a limited role in treating veno-occlusive dysfunction only in highly selected men with minimal cavernosal smooth muscle dysfunction. Hypoxemia, sleep apnea and respiratory failure may also affect erectile dysfunction. However, little attention has been paid to oxygen as therapy for ED. CONCLUSIONS: Current therapy, while effective in circumventing vasculogenic ED, is relatively ineffective in permanently reversing the condition. Further research aimed at long-term treatment strategies in vasculogenic ED is needed. |
| | |
Authors:
|
Mike B Siroky; Kazem M Azadzoi |
Related Documents
:
|
10853939 - Correlation of clinical and neuroradiological findings in down-gaze palsy. 15918449 - Coagulation management of a patient with factor v leiden mutation, lupus anticoagulant,... 10613979 - Anticoagulation in congestive cardiomyopathy: steps toward defining the great unknown. 18840579 - Whole blood hypercoagulability despite anticoagulation during mechanical cardiac assist. 16188499 - Ventricular remodeling in loeffler endocarditis: implications for therapeutic decision ... 17574129 - 3d and 2d delayed-enhancement magnetic resonance imaging for detection of myocardial in... 16214839 - Interaction between at1 and at2 receptors during postinfarction left ventricular remode... 20381669 - Value of tissue doppler echocardiography in predicting response to cardiac resynchroniz... 21752089 - Unusual left atrial mass: inverted left atrial appendage caused by massive pericardial ... |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: The Journal of urology Volume: 170 ISSN: 0022-5347 ISO Abbreviation: J. Urol. Publication Date: 2003 Aug |
Date Detail:
|
Created Date: 2003-07-10 Completed Date: 2003-08-04 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 0376374 Medline TA: J Urol Country: United States |
Other Details:
|
Languages: eng Pagination: S24-9; discussion S29-30 Citation Subset: AIM; IM |
Affiliation:
|
Boston Veterans Administration Medical Center, 150 South Huntington Ave., Room A4-43, Boston, Massachusetts 02130, USA. msiroky@bu.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Disease Models, Animal Endothelial Growth Factors / pharmacology Erectile Dysfunction / drug therapy*, physiopathology* Fibrosis Humans Intercellular Signaling Peptides and Proteins / pharmacology Life Style Lymphokines / pharmacology Male Muscle, Smooth / pathology Nitric Oxide / physiology Penile Erection / physiology* Penis / blood supply Protein Isoforms / pharmacology Regional Blood Flow Treatment Outcome Vascular Endothelial Growth Factor A Vascular Endothelial Growth Factors |
| Chemical | |
Reg. No./Substance:
|
0/Endothelial Growth Factors; 0/Intercellular Signaling Peptides and Proteins; 0/Lymphokines; 0/Protein Isoforms; 0/Vascular Endothelial Growth Factor A; 0/Vascular Endothelial Growth Factors; 10102-43-9/Nitric Oxide |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Viability and safety of combination drug therapies for erectile dysfunction.
Next Document: Neuroprotection and nerve grafts in the treatment of neurogenic erectile dysfunction.